Intelligent Bio-Systems Lands $600K SBIR from NIAID to Develop Sequence-Based HIV Test
NEW YORK (GenomeWeb News) - Intelligent Bio-Systems has received a $600,000, two-year Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease to develop a DNA-sequencing-based test that would detect and quantify drug-resistant variants of HIV-1, the company said today.
IBS licenses its sequencing-by-synthesis technology through a deal with the Columbia Genome Center at Columbia University. As GenomeWeb News reported in December the company is developing its sequencing platform and expects to launch it commercially sometime in 2008.
Although current methods of drug-resistant genotyping can detect this virus only above 20 percent abundance, IBS’ VP of R&D, Jerzy Olejnik, said the company's sequencing technology can detect the virus at 1 percent or less abundance.
Detecting drug resistance at lower levels could enhance the ability of physicians to plan their treatment regimens, the company said.